Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apidra Dosing Frequency in Type 2 Diabetes
NCT00135083Phase 3Completed
- Sponsor
- Sanofi
- Start
- Aug 2004
- Modality
- Peptides
01
Overview
A Phase 3 trial of insulin glulisine in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Started Aug 2004; status: completed.
02
Drugs
insulin glulisine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00135083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00135083.